A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

NCT07672561 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: Drug:WD-890
DRUG: Drug: placebo

Sponsor

Zhejiang Wenda Pharma Technology LTD.